헤마테인을 함유하는 고지혈증 및 동맥경화증 예방 및치료용 조성물
    2.
    发明公开
    헤마테인을 함유하는 고지혈증 및 동맥경화증 예방 및치료용 조성물 失效
    用于预防和治疗包括HEMATEIN的ATHEROSCLEROSIS和HYPERLIPIDEMIA的组合物

    公开(公告)号:KR1020020060115A

    公开(公告)日:2002-07-16

    申请号:KR1020020027396

    申请日:2002-05-17

    Abstract: PURPOSE: A pharmaceutical composition containing hematein which is obtainable by extraction of Heartwood of Caesalpinia sappan or commercially as an active ingredient is provided. Because the hematein exhibits LDL-antioxidant activity, remarkably reduces cholesterol in blood and strongly inhibits liver microsome ACAT activity, the composition can be effectively used in prevention and therapeutic treatment of atherosclerosis and hyperlipidemia. CONSTITUTION: The composition for preventing and treating atherosclerosis and hyperlipidemia in mammals contains an effective amount of hematein and a pharmaceutically acceptable carrier as an active component. The hematein inhibits the activity of acyl-CoA : cholesterol acyltransferase or acts as LDL-antioxidant to give an effect on preventing and treating hyperlipidemia.

    Abstract translation: 目的:提供含有作为活性成分的可以通过提取凯萨金(Caesalpinia sappan)心材或商业获得的含有hematein的药物组合物。 由于唾液酸显示低密度脂蛋白抗氧化活性,显着降低血液中的胆固醇,强烈抑制肝微粒体ACAT活性,可有效用于动脉粥样硬化和高脂血症的预防和治疗。 构成:用于预防和治疗哺乳动物动脉粥样硬化和高脂血症的组合物含有有效量的hematein和药学上可接受的载体作为活性成分。 半乳糖苷抑制酰基辅酶A:胆固醇酰基转移酶的活性或作为低密度脂蛋白抗氧化剂,以预防和治疗高脂血症。

    혈소판 활성인자 수용체 결합에 대하여 길항활성을 갖는 물질 및 이것을 함유하는 약학적 조성물의 용도
    3.
    发明授权

    公开(公告)号:KR100270912B1

    公开(公告)日:2000-10-16

    申请号:KR1019990024335

    申请日:1999-06-25

    Abstract: PURPOSE: Schizandrin having antagonistic activity on a platelet activating factor receptor isolated from Schisandrae fructus, a pharmaceutical composition containing the compound, pharmaceutically acceptable carrier and excipient and their use are provided. Therefore the composition can be used for treatment and prevention of inflammatory disease related to a platelet activating factor. CONSTITUTION: An antagonist on a platelet activating factor receptor contains schizandrin A, B or C of formula 3 isolated from Schisandrae fructus as an effective component. In formula, a compound in which R1, R2, R3 and R4 are respectively CH3O is schizandrin A; a compound in which R1 and R2 are respectively CH3O, and R3 and R4 are connected to OCH2O is schizandrin B; and a compound in which R3 and R4 are connected to OCH2O is schizandrin C. A pharmaceutical composition for treatment and prevention of inflammatory disease related to a platelet activating factor contains the schizandrin, pharmaceutically acceptable carrier and excipient.

    Abstract translation: 目的:提供对从五味子分离的血小板活化因子受体具有拮抗作用的五味子,含有该化合物,药学上可接受的载体和赋形剂的药物组合物及其用途。 因此,该组合物可用于治疗和预防与血小板激活因子相关的炎性疾病。 构成:血小板活化因子受体上的拮抗剂含有从五味子中分离的式3的五味子素A,B或C作为有效成分。 在式中,R 1,R 2,R 3和R 4分别为CH 3 O的化合物为五味子二; 其中R1和R2分别为CH3O,R3和R4连接到OCH2O的化合物是五味子二; 和其中R 3和R 4连接到OCH 2 O的化合物是五味子三嗪C.用于治疗和预防与血小板活化因子相关的炎性疾病的药物组合物含有五味子三糖,药学上可接受的载体和赋形剂。

    류코트리엔생성저해활성을가지는정유성분
    4.
    发明公开
    류코트리엔생성저해활성을가지는정유성분 失效
    含有基本油的药物组合物作为抑制白藜芦醇生产的主要原则

    公开(公告)号:KR1020000040361A

    公开(公告)日:2000-07-05

    申请号:KR1019980055981

    申请日:1998-12-18

    Abstract: PURPOSE: A pharmaceutical composition containing essential oil as an active principle for inhibiting production of leukotriene is useful for prevention and treatment of the diseases related with the activity of leukotriene such as asthma, cystic fibrosis, septic shock, cardiac anaphylaxis, cerebral vasospasm, psoriasis, endotoxemia, myocardial ischemia, etc.. CONSTITUTION: A main component of the essential oil is more than one compound selected from (-)-menthol, (+)-limonene, alpha-terpinene, gamma-terpinene, terpineol, beta-myrcene, (+or-)-linalool, geraniol, citral, beta-cyclocitral, eugenol, safrol, (+)-alpha-pinene, (-)-alpha-pinene and (+)-cis-verbenol.

    Abstract translation: 目的:含有精油作为抑制白细胞三烯生成的活性成分的药物组合物可用于预防和治疗与白细胞三烯的活性有关的疾病,例如哮喘,囊性纤维化,败血性休克,心脏过敏反应,脑血管痉挛,牛皮癣, 内毒素血症,心肌缺血等。组成:精油的主要成分是选自( - ) - 薄荷醇,(+) - 柠檬烯,α-萜品烯,γ-萜品烯,萜品醇,β-月桂烯, (+或 - ) - 芳樟醇,香叶醇,柠檬醛,β-环咔唑,丁子香酚,safrol,(+) - 蒎烯,( - ) - 蒎烯和(+) - 顺式 -

    헤마테인을 함유하는 고지혈증 및 동맥경화증 예방 및치료용 조성물
    6.
    发明授权
    헤마테인을 함유하는 고지혈증 및 동맥경화증 예방 및치료용 조성물 失效
    含有血红素的高脂血症和动脉硬化的预防和治疗组合物

    公开(公告)号:KR100362940B1

    公开(公告)日:2002-11-30

    申请号:KR1020020027396

    申请日:2002-05-17

    Abstract: 본발명은유효량의헤마테인을함유하는고지혈증및 동맥경화증예방및 치료용조성물에관한것으로, 본발명의조성물은의약용및 식품용조성물을포함한다. 헤마테인은 LDL-항산화제활성을나타내며, 혈중콜레스테롤을현저하게감소시키고, 간마이크로좀 ACAT 활성을강력하게저해하므로, 헤마테인을함유하는본 발명의조성물은고지혈증및 동맥경화증의치료및 예방을위해유용하게사용될수 있다.

    Abstract translation: 本发明涉及含有有效量的伴侣H.的高脂血症和动脉硬化的预防和治疗组合物,包括本发明和医疗食物组合物为的组合物。 H.伴侣-在LDL-抗氧化剂是指活性,显著降低血液中的胆固醇,将含有微粒体肝ACAT本发明的组合物中,H.配合,从而强烈地抑制高脂血症和动脉粥样硬化的治疗和预防的活性 可以有用地用于。

    헤마테인을 함유하는 고지혈증 및 동맥경화증 예방 및 치료용 조성물
    7.
    发明公开
    헤마테인을 함유하는 고지혈증 및 동맥경화증 예방 및 치료용 조성물 失效
    用于保护或治疗含有高脂血症的药物组合物和含有HAEMATIN的阿片样物质

    公开(公告)号:KR1020000073945A

    公开(公告)日:2000-12-05

    申请号:KR1019990017558

    申请日:1999-05-17

    Abstract: PURPOSE: A haematin substance has characteristically an LDL(low density lipoprotein)-antioxidation, reduces the concentration of cholesterol in blood, and inhibits the activity of liver microsome ACAT(acyl-CoA: cholesterol acyl-transferase). Thereby, the pharmaceutical composition containing the haematin has an excellent effect for treating or protecting specific diseases such as hyperlipidemia or arteriosclerosis. CONSTITUTION: The haematin used is conventionally derivable from Heartwood of Caesalpinia sappan, or is available industrially. The pharmaceutical composition is used to treat or protect hyperlipidemia or arteriosclerosis by using usual haematin in drug, beverage or food.

    Abstract translation: 目的:血红素物质具有LDL(低密度脂蛋白) - 抗氧化作用,降低血液中胆固醇的浓度,并抑制肝微粒体ACAT(酰基辅酶A:胆固醇酰基转移酶)的活性。 因此,含有血红素的药物组合物对治疗或保护特异性疾病如高脂血症或动脉硬化具有优异的效果。 构成:所使用的血红素通常衍生自凯撒山茱萸的心材,或在工业上可用。 药物组合物用于通过在药物,饮料或食物中使用普通血红素来治疗或保护高脂血症或动脉硬化。

    류코트리엔 생성 저해활성을 가지는 정유 성분
    9.
    发明授权
    류코트리엔 생성 저해활성을 가지는 정유 성분 失效
    류코트리엔생성저해활성을가지는정유성분

    公开(公告)号:KR100372562B1

    公开(公告)日:2003-02-15

    申请号:KR1020010049577

    申请日:2001-08-17

    Abstract: PURPOSE: Provided is a novel use of essential oil obtained by vapor distillation of plants and showing the inhibitory action against the production of leukotriene as a mediator of inflammation. CONSTITUTION: An inhibitor of leukotriene production comprises at least a compound selected from the group consisting of (-)-menthol, (+)-limonene, alpha-terpinene, gamma-terpinene, terpineol, beta-myrcene, (±)-linaloo, geraniol, citral, beta-cyclocitral, eugenol, safrole, (+)-alpha-pinene, (-)-alpha-pinene, and (+)-cis-verbenol, as an effective components. Preferably, the inhibitor comprises eugenol or safrole as an active ingredient. The inhibitor can be used for a variety of inflammatory diseases including asthma, whooping cough, psoriasis, arthritis, inflammatory intestine diseases, cystic fibrosis, chronic bronchitis, rheumatoid arthritis, septic shock, myocardial ischemia, cardiac anaphylaxis, cerebral vasospasm, ischemia and allergic rhinitis.

    Abstract translation: 目的:提供一种通过蒸馏植物而获得的精油的新用途,并显示出对作为炎症介质的白三烯产生的抑制作用。 ( - ) - 薄荷醇,(+) - 柠檬烯,α-萜品烯,γ-萜品烯,萜品醇,β-月桂烯,(+); (+) - α-蒎烯,( - ) - α-蒎烯,和(+) - 顺式 - 马鞭草醇为有效成分。 优选地,抑制剂包含丁香酚或黄樟素作为活性成分。 该抑制剂可用于哮喘,百日咳,牛皮癣,关节炎,炎性肠疾病,囊性纤维化,慢性支气管炎,类风湿性关节炎,感染性休克,心肌缺血,心脏过敏反应,脑血管痉挛,局部缺血和过敏性鼻炎 。

    류코트리엔생성저해활성을가지는정유성분
    10.
    发明授权
    류코트리엔생성저해활성을가지는정유성분 失效
    具有白三烯生成抑制活性的精油组分

    公开(公告)号:KR100355497B1

    公开(公告)日:2002-12-28

    申请号:KR1019980055981

    申请日:1998-12-18

    Abstract: 본 발명은 정유 (精油; essential oil)를 유효성분으로 함유하는 류코트리엔 생성 저해제용 약학적 조성물에 관한 것으로, 보다 상세하게는 주성분으로 (-)-멘틀 (menthol; 화학식 1), (+)-리모넨 (limonene; 화학식 2),
    α -테르피넨 (terplnelle; 화학식 3),
    r -테르피넨 (terpinene; 화학식 4), 테르퍼네올 (terpineol; 화학식 5),
    β -미르센 (myrcene; 화학식 6), (±)-리나룰 (linalool; 화학식 7), 게라니올 (geraniol; 화학식 8), 사이트랄 (citral; 화학식 9),
    β -사이클로사이트랄 (cyclocitral; 화학식 10), 유게놀 (eugenol; 화학식 11), 사프롤 (safrole; 화학식 12), (+)-
    α -피넨 (pinene; 화학식 13), (-)-
    α -피넨 (pinene; 화학식 14) 및 (+)-
    cis -베르베놀 (verbenol; 화학식 15) 중에서 선택되는 하나 이상의 화합물을 포함하는 조성물은 류코트리엔 생성 저해제로서 류코트리엔과 관련된 질환의 예방, 치료 및 치료보조제 로 유용하게 사용될 수 있다.

Patent Agency Ranking